N-acetylcysteine treatment in viral-induced acute liver failure

Simple item page
dc.contributor.authorNabi, Tauseefen_US
dc.contributor.authorRafiq, Nadeemaen_US
dc.date.accessioned2020-05-06T08:33:34Z
dc.date.available2020-05-06T08:33:34Z
dc.date.issued2019-07
dc.description.abstractBackground:Acute liver failure (ALF) is characterized by acute derangement of liver function and carries high mortality. Viral hepatitis is still one of the main causes of ALF in the India as well in world. A prospective case control study was carried with the aim to determine the effect of N-acetylcysteine (NAC) on survival ofviral-ALFpatients.Methods:37 patients with a diagnosis of viral-ALFwere included in the study. 18 patients received NAC infusion for 72hrs whereas 19 patients in control group received placebo. The variables evaluated were demographic, biochemical, outcome and length of hospital stay.Results:Out of 37viral-ALFpatients, acute HEV-induced ALF (48.6%) was most common followed by HBV (24.3%) and HAV (21.6%). The two groups were comparable for the various baseline characteristics (age, INR, bilirubin,ALT, creatinine, albumin, grade of encephalopathy,mean grade of comaetc.). Use of NAC was associated with a shorter length of hospital stay of survived patients (p=0.024). A total of 20 of 37 (54.1%) patients died with ALF complications; 7 (38.9%) patients belonged to NACgroup and 13 (68.4%) patients to control group (p=0.079).HEV induced ALFshowed significant improved in survival than Non HEV inducedALF with NAC administration (p=0.022). Conclusions: HEV was the most frequently cause ofviral-ALF. Overall survival was not improved by NAC. HEV induced ALFshowed significant improved in survival than Non HEV inducedALF with NAC administration.NAC reduced duration of hospital stayen_US
dc.identifier.affiliationsDepartment of Endocrinology, Government Medical College, Srinagar, Jammu and Kashmir, Indiaen_US
dc.identifier.affiliationsDepartment of Physiology, Government Medical College, Baramulla, Jammu anden_US
dc.identifier.citationNabi Tauseef, Rafiq Nadeema. N-acetylcysteine treatment in viral-induced acute liver failure. International Journal of Clinical Trials. 2019 Jul; 6(3): 106-111en_US
dc.identifier.issn2349-3240
dc.identifier.issn2349-3259
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/200922
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber3en_US
dc.relation.volume6en_US
dc.source.urihttps://dx.doi.org/10.18203/2349-3259.ijct20193213en_US
dc.subjectAcute liver failureen_US
dc.subjectViral-ALFen_US
dc.subjectHepatic encephalopathyen_US
dc.subjectHepatitis E virusen_US
dc.subjectN-acetylcysteineen_US
dc.titleN-acetylcysteine treatment in viral-induced acute liver failureen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijct2019v6n3p106.pdf
Size:
334.31 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Clinical Trials